Poster Presentation ESA-SRB 2023 in conjunction with ENSA

Mineralocorticoid receptor antagonist treatment for low-renin hypertension: a systematic review and meta-analysis (#275)

Sonali S Shah 1 2 , Jinghong Zhang 2 , Stella May Gwini 2 , Morag J Young 2 , Peter J Fuller 1 2 , Jun Yang 1 2
  1. Endocrinology, Monash Health, Clayton, VIC, Australia
  2. Centre of Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC , Australia
Publish consent withheld
  1. Australian Institute of Health and Welfare. Biomedical risk factors [Internet]. Canberra: Australian Institute of Health and Welfare, 2022 [cited 2023 Jul. 27]. Available from: https://www.aihw.gov.au/reports/australias-health/biomedical-risk-factors
  2. Funder JW. Primary aldosteronism and low-renin hypertension: a continuum? Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2013;28:1625-1627